Microcap Ledger Fulgent Genetics, Inc. $FLGT
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Services-Medical Laboratories
- Headquarters
- El Monte, CA
- Fiscal year end
- December 31
- Shares outstanding
- 27,515,293 [10-Q 2026-07-30]
What the company doesAI summary of filing
Fulgent Genetics is a revenue-generating technology company with two business divisions. Its laboratory services business provides anatomic pathology testing, precision diagnostics testing including NGS-based tests for rare disease and hereditary cancer, and specialized oncology services to insurance payors, institutional customers, and direct-pay patients through CLIA-certified U.S. laboratories and a telemedicine platform called Picture. The company also operates Fulgent Pharma, a therapeutic development business focused on developing cancer drug candidates using a nanoencapsulation platform technology; two product candidates, FID-007 and FID-022, are currently in clinical trials, and preclinical development of antibody-drug conjugates is underway. The company generates revenue primarily from laboratory testing services billed to payors and customers. [10-K 2026-02-27]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $156.53M | −$54.36M | −$16.66M | $26.30M | [10-Q 2026-07-30] |
| FY ended Dec 2025 | $322.67M | −$60.51M | −$101.64M | $50.19M | [10-K 2026-02-27] |
| FY ended Dec 2024 | $283.47M | −$42.71M | $21.06M | $55.14M | [10-K 2026-02-27] |
- Quarterly cash burn
- −$8.33M
- Cash runway Estimate
- ~9.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-04 | 30,586,811 | [10-Q 2024-11-08] |
| 2025-02-24 | 30,829,454 | [10-K 2025-02-28] |
| 2025-04-28 | 30,443,595 | [10-Q 2025-05-02] |
| 2025-07-28 | 30,609,044 | [10-Q 2025-08-01] |
| 2025-11-03 | 30,912,392 | [10-Q 2025-11-07] |
| 2026-02-23 | 31,230,632 | [10-K 2026-02-27] |
| 2026-04-27 | 28,400,623 | [10-Q 2026-05-01] |
| 2026-07-27 | 27,515,293 | [10-Q 2026-07-30] |
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-02 | Gao Hanlin | sell | 1,673 | $19.66 | [4 2026-09-03] |
| 2026-09-02 | Xie Jian | sell | 2,127 | $19.66 | [4 2026-09-03] |
| 2026-09-01 | Kim Paul | other | 2,087 | $19.59 | [4 2026-09-03] |
| 2026-09-01 | Hsieh Ming | other | 4,392 | $19.59 | [4 2026-09-03] |
| 2026-08-27 | Xie Jian | sell | 1,193 | $19.91 | [4 2026-08-28] |
| 2026-08-27 | Gao Hanlin | sell | 939 | $19.91 | [4 2026-08-28] |
| 2026-08-26 | Hsieh Ming | other | 2,949 | $19.81 | [4 2026-08-28] |
| 2026-08-26 | Kim Paul | other | 1,168 | $19.81 | [4 2026-08-28] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-07-30 | 10-Q | Quarterly report |
| 2026-07-30 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-06-02 | 8-K | Other events |
| 2026-05-27 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-05-21 | 8-K | Other events |
| 2026-05-14 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-01 | 10-Q | Quarterly report |
| 2026-05-01 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-03-31 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-03-31 | DEF 14A | Proxy statement |
| 2026-03-17 | 8-K | Material agreement entered; Acquisition or disposition completed; Regulation FD disclosure |
| 2026-02-27 | 10-K | Annual report |
Alerts for $FLGT
Email me when Fulgent Genetics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.